Revance Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Revance Therapeutics (RVNC) Prices 3.25M Common Offering at $36/Share
November 4, 2015 7:08 AM ESTRevance Therapeutics (NASDAQ: RVNC) announced the pricing of its underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $36.00 per share. Revance also granted the underwriters a 30-day option to acquire an additional 487,500 shares from Revance. The offering... More
Revance Therapeutics (RVNC) Announces 3.25M Stock Offering
November 2, 2015 6:25 AM ESTRevance Therapeutics (NASDAQ: RVNC) announced a proposed underwritten public offering of 3,250,000 shares of its common stock. Revance expects to grant the underwriters a 30-day option to acquire an additional 487,500shares. The offering is subject to market and other conditions, and there... More
